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Discovering the mechanisms underlying serotonin (5-HT)2A and 5-HT2C receptor regulation 
following nicotine withdrawal in rats 
 
Abstract 
We have previously demonstrated that nicotine withdrawal produces depression-like behavior 
and that serotonin (5-HT)2A/2C receptor ligands modulate that mood-like state. In the present 
study we aimed to identify the mechanisms (changes in radioligand binding, transcription or 
RNA-editing) related to such a behavioral outcome. Rats received vehicle or nicotine (0.4 mg/kg, 
sc) for 5 days in home cages. Brain 5-HT2A/2C receptors were analyzed on day 3 of nicotine 
withdrawal. Nicotine withdrawal increased [3H]ketanserin binding to 5-HT2A receptors in the 
ventral tegmental area and ventral dentate gyrus, yet decreased binding in the nucleus accumbens 
shell. Reduction of [3H]mesulergine binding to 5-HT2C receptors was seen in the ventral dentate 
gyrus. Profound decrease in the 5-HT2A receptor transcript level was noted in the hippocampus 
and ventral tegmental area. Out of five 5-HT2C receptor mRNA editing sites, deep sequencing 
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 data showed a reduction in editing at the E site and a trend toward reduction at the C site in the 
hippocampus. In the ventral tegmental area, a reduction for the frequency of CD 5-HT2C receptor 
transcript was seen. These results show that the reduction in the 5-HT2A receptor transcript level 
may be an auto-regulatory response to the increased receptor density in the hippocampus and 
ventral tegmental area during nicotine withdrawal, while decreased 5-HT2C receptor mRNA 
editing may explain the reduction of receptor labelling in the hippocampus. 
 
Introduction 
Nicotine is one of the major psychoactive constituents of tobacco smoke that has a strong abuse 
potential in humans and laboratory animals. The most common withdrawal symptoms in humans 
include nicotine craving, irritability, anxiety, difficulty of concentration, increased appetite and 
depressed mood (reviewed by Kenny and Markou, 2001; Markou, 2008). Prevention of the latter 
mood state has become an important issue in the management of nicotine-use or addiction.  
Many pharmaco-behavioral studies have shown that withdrawal from chronic nicotine 
exposure produced depression-like behavior in mice (15-day voluntary drug intake or passive 
drug administration) and rats (experimenter-delivered drug for 5 days), as measured by 
exaggerated immobility time in the forced swim test (Mannucci et al., 2006; Ribeiro-Carvalho et 
al., 2011; Zaniewska et al., 2010). The above data also showed that such behavioral sequelae 
were either completely diminished by the 5-HT precursor 5-hydroxytryptophan, or were 
attenuated by 5-HT2A receptor antagonists or 5-HT2C receptor agonists (Mannuci et al., 2006; 
Zaniewska et al., 2010). During withdrawal from repeated nicotine exposure (delivered by the 
experimenter or through osmotic mini-pumps) profound changes in the 5-HT system (i.e., 
significant reductions in brain 5-HT content and/or neurotransmitter turnover) have been found 
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 (Benwell and Balfour, 1979; Mannuci et al., 2006; Slotkin and Seidler, 2007; Yasuda et al., 
2002) and were further linked to the functional supersensitivity of 5-HT2A (Suemaru et al., 2001; 
Zaniewska et al., 2009) and 5-HT2C receptors (Zaniewska et al., 2010).  
5-HT2A and 5-HT2C receptor-mediated neurotransmission can be regulated at multiple 
levels, including transcription (alterations at the transcription level), post-transcriptional RNA 
processing (alternative splicing), post-translational modifications, trafficking and protein 
complex formation. Additionally, the expression of the 5-HT2C, but not the 5-HT2A, receptor 
gene can be post-transcriptionally regulated by RNA editing (Fig. 1) (Burns et al., 1997; 
Niswender et al., 1998). Importantly, the 5-HT2C receptor is the only known G protein coupled 
receptor that was shown to undergo editing. In this process, adenosine deaminases acting on 
RNA (ADARs) convert one or more of five closely spaced adenosine residues (termed A, B, E, 
C and D editing sites) into inosines which are read as guanosines by the translational machinery. 
Changes in gene-encoded Ile, Asn and Ile (INI) at positions 156, 158 and 160 (in humans), 
located within the second intracellular loop of the receptor, may lead to the generation of up to 
24 protein isoforms. These RNA-edited 5-HT2C receptor isoforms have differential distribution 
patterns throughout the brain and, as evidenced by in vitro or in vivo studies, may have very 
different receptor function, including changes in constitutive activity, as well as altered agonist 
potency, ligand binding affinity and selectivity of G-protein coupling (Berg et al., 2001; Burns et 
al., 1997; Fitzgerald et al., 1999; Herrick-Davis et al., 1999; Niswender et al., 1999; Olaghere da 
Silva et al., 2010; Price et al., 2001; Wang et al., 2000). Furthermore, editing has been shown to 
affect alternative splicing (Martin et al., 2013) or drive receptor localization, i.e., enhance cell 
surface expression of highly edited 5-HT2C receptors (VGV isoform) by modulating intracellular 
trafficking efficacy (Marion et al., 2004).  
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 Studies in humans have revealed a link between changes in 5-HT2C receptor RNA editing 
and psychiatric disorders, including depression (Gurevich et al., 2002b; Iwamoto and Kato, 
2003; Lyddon et al., 2013). Similarly, a modified profile of RNA-edited receptor isoforms was 
reported in rodents with depression-like phenotypes or reduced brain 5-HT levels which are 
regarded as core to depression (Bhansali et al., 2007; Gurevich et al., 2002a; Iwamoto et al., 
2005). To date, the impact of nicotine withdrawal-induced depression-like behavior on 5-HT2C 
receptor editing has not yet been studied. 
 
 Taken together, the behavioral and biochemical data prompted us to verify the 
hypothesis that exposure to nicotine followed by withdrawal induces changes in the binding 
pattern and gene expression of 5-HT2A and 5-HT2C receptors. We therefore administered nicotine 
for five days and on day 3 of drug withdrawal animals were sacrificed and changes in brain 5-
HT2A and 5-HT2C receptors were analyzed. We have previously demonstrated that 5-day nicotine 
injections induced behavioral sensitization and conditioned locomotor activity in rats and such a 
dosing schedule has been shown to produce changes in the 5-HT2A and 5-HT2C receptor labeling 
in the brain (Zaniewska et al., 2015). The same treatment was accompanied by increased BOLD 
response in the brain regions related to drug addiction, including the hippocampus, nucleus 
accumbens, prefrontal cortex or ventral tegmentum (Li et al., 2008) or induced dopamine release 
in the nucleus accumbens in rats (Rahman et al., 2007) similarly as tobacco smoking in humans 
(Cosgrove et al., 2014). Thus, this animal model serves as a relevant initial screening method not 
only for evaluating the potential therapeutic efficacy of novel drugs, but also for evaluating the 
cellular and molecular changes following exposure to nicotine. The early withdrawal period was 
chosen based on previous data, demonstrating maximal depression-like effects (an increase in 
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 immobility time in the forced swim test) on this day of drug cessation and efficacy of 5-HT2A/2C 
receptor ligands in attenuating this mood-like state (Zaniewska et al., 2010). Here we enrich the 
previously published behavioral data (Zaniewska et al., 2010) from day 3 of nicotine withdrawal 
by showing other parameters: swimming and climbing. Receptor autoradiography was analyzed 
in several brain areas (Fig. 2A) in which 5-HT2A or 5-HT2C receptors are known to be present 
(López-Giménez et al., 2002) and/or that are essential in the process of nicotine withdrawal 
(Malin and Goyarzu, 2009). The transcript level of 5-HT2A receptors was analyzed only in these 
brain structures (the hippocampus and ventral tegmental area) in which the robust (> 50%) 
changes in radioligand binding were reported. Analogous brain areas were chosen to assess 5-
HT2C receptor mRNA level and editing. Both these brain regions are implicated in nicotine 
dependence and depression-like behavior in rodents (Cohen et al., 2015; Drevets et al., 2008; 
Malin and Goyarzu, 2009). In addition, in the hippocampus we noted significant changes in 
radioligand binding to 5-HT2C receptors. Transcript level was analyzed by real time PCR. Deep 
sequencing technology was used to gain information about the 5-HT2C receptor mRNA editing. 
 
Material and Methods 
Animals 
Male Wistar rats (Charles River, Germany) weighing 220-250 g (9 weeks old) at the beginning 
of the experiment were used. The animals were housed 4-7 per cage (58 cm x 37 cm x 20 cm) in 
a colony room maintained at 21 ± 1ºC and 40-50% humidity under a 12-h light-dark cycle (lights 
on at 6:00). Rodent chow and water were available ad libitum. All the experiments were 
conducted during the light phase of the light-dark cycle (8:00-14:00), in accordance with The 
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 National Institutes of Health Guide for the Care and Use of Laboratory Animals and the 
approval of the Bioethics Commission (at the Institute of Pharmacology Polish Academy of 
Sciences) and compliant with the Polish Law (August 21, 1997). All the efforts were made to 
minimize animal suffering and to reduce the number of rats used.  
 
Repeated nicotine administration 
Drugs 
(-)-Nicotine bitartrate (Sigma-Aldrich, USA) was dissolved in 0.9% saline. The pH was adjusted 
to 7.0 using 20% NaOH. Drug was injected subcutaneously in a volume of 1 ml/kg. The dose of 
nicotine (expressed as that of the free base) and pretreatment time were optimized in our 
laboratory, as described previously (Zaniewska et al., 2010).  
Measurement of depression-like behavior in animals withdrawn from nicotine  
Rats were given nicotine (0.4 mg/kg) or vehicle (1 ml/kg) for 5 days in home cages. The forced 
swim test was performed on day 3 of nicotine withdrawal. 
Forced swim test 
On the first day of forced swim test, rats withdrawn from nicotine were placed individually in a 
cylinder (50-cm high and 23 cm in diameter) filled with 30 cm of water (25 ± 1°C) for 15 min 
(the pre-test). They were then removed, dried with towels, and placed in a warmer enclosure for 
15 min before they were returned to their home cages. The cylinders were emptied and cleaned 
between rats. 24 h after the pre-test, the rats were retested for 5 min under identical conditions. 
Two blinded observers scored each retest session. The following parameters were measured 
manually: the immobility, swimming and climbing. A rat was rated to be immobile if it was 
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 making only movements necessary to keep its head above water; swimming was recorded if a rat 
was actively making swimming movement that caused it to move within the center of cylinder 
and swim below the surface of water (diving); climbing behavior was recorded if a rat was 
making forceful thrashing movements with its forelimbs against the walls of cylinder.  
Withdrawal from chronic nicotine treatment 
Animals were given nicotine (0.4 mg/kg) or vehicle (1 ml/kg) for 5 days in home cages. 
Following 3 days of nicotine withdrawal, animals were killed by decapitation and their brain 5-
HT2A/2C receptors were analyzed by receptor autoradiography, real time PCR or deep sequencing.   
 
Quantitative receptor autoradiography 
Immediately after decapitation, the brains were dissected, frozen on dry-ice and stored at  
-70°C until use. Frozen brains were cut on a cryostat (Leica Cm 1850, Germany) at -22 ± 1°C. 
12-µm sections were then mounted on a single gelatin-coated slide (5 coronal sections per each 
slide; Fig. 2A) and kept at -20°C until assayed. Autoradiographic analyses were performed 
according to the method of Syvälahti et al. (2006) with certain modifications (Zaniewska et al., 
2015). Briefly, the 5-HT2A receptor antagonist [ethylene-3H]ketanserin hydrochloride (Perkin 
Elmer, USA; 1 nM; s.a.: 67.0 Ci/mmol) and the 5-HT2C receptor inverse agonist [N6-methyl-
3H]mesulergine (Amersham Biosciences; 4.2 nM; s.a.: 67.0 Ci/mmol) were used as radioligands. 
The slides were first pre-incubated in Buffer A (170 mM Tris-HCl; Sigma-Aldrich; pH 7.5). 
Next, the incubation was performed in Buffer A containing the appropriate radioligand and the 
blocking substance I (prazosin hydrochloride (Tocris Bioscience, UK; 1 μM; to block 
[3H]ketanserin binding to α1-adrenoceptors) or spiperone hydrochloride (Sigma-Aldrich; 100 
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 nM; to block [3H]mesulergine binding to 5-HT2A receptors)) (total binding: T). The non-specific 
binding (NS) was quantified by incubating separate sections in Buffer A with the appropriate 
radioligand, blocking substance I, and blocking substance II (M100,907 (Abbott Healthcare 
Products B.V., The Netherlands; 5 μM; 5-HT2A receptor autoradiography) or methysergide 
maleate (Tocris Bioscience; 5 μM; 5-HT2C receptor autoradiography)). After the incubation, all 
slides were washed in Buffer A and then in distilled water.  
Radiolabeled dried tissue sections were exposed to tritium-sensitive screens (The Bass 
IP-TR, 20 cm x 25 cm, Fujifilm, Japan) in photosensitive cassettes (The Bass IP Cassettes, 20 cm 
x 25 cm, Fujifilm) together with the autoradiographic [3H]microscale (Amersham Biosciences). 
Images were read by Image Reader v.1.1 (The Bass-5000 IP, Fujifilm). Quantitative analysis of 
autoradiograms was performed using Multi Gauge 3.0 software (Fujifilm). Optical densities of 
grey values on the film (relative optical density) were converted into bound radioactivity using 
the standard polynomial regression curve as a standard. Optical densities, which were the 
differences between the optical density of T and NS binding, were expressed as nCi/mg tissue 
relative to the specific activity of the appropriate radioligand. Changes in receptor labeling are 
expressed in fmol of bound radioligand per mg of tissue (± SEM) and are also presented as the 
mean percentage of changes with relation to the control value (100%). 
Brain structures were identified by a comparison of autoradiographic images with 
appropriate figures from the rat brain atlas of Paxinos and Watson (1998). Measurement of the 
optical densities of 5-HT2A and 5-HT2C receptors was performed on both sides of the frontal 
cortex, prefrontal (cingulate, infralimbic and prelimbic) cortex, claustrum, dorsal striatum, 
nucleus accumbens, hippocampus (ventral dentate gyrus) and ventral tegmental area, and 
additionally – in the case of 5-HT2C receptors – the lateral septum, thalamus, amygdala, 
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 substantia nigra and choroid plexus (Fig. 2B, C). Only the data from these brain structures in 
which significant changes in 5-HT2A and 5-HT2C receptor labeling were noted following 
withdrawal from chronic nicotine treatment are shown in the paper (Fig. 2A). 
 
Sample preparation for transcript analyses 
The transcript level of 5-HT2A and 5-HT2C receptors and editing status of 5-HT2C receptor mRNA 
were analyzed in the hippocampus and ventral tegmental area. Immediately after the end of 
behavioral procedure (the same nicotine dosing schedule as for autoradiography analysis), 
animals were killed by decapitation and the brains were rapidly dissected and chilled in ice-cold 
saline. The brain was positioned ventral side up and a coronal cut was made at the level of the 
mammillary nuclei (its posterior end; approximately 5.6 mm posterior to bregma). The ventral 
tegmental area was dissected out by making a ca. 1.5-mm punch (around 0.5 to 2.0 mm dorsal to 
the ventral edge of the anterior brain portion). Next, the hippocampus (including dentate gyrus, 
CA3, CA2, CA1 and subiculum) was dissected out. Tissues were frozen on dry ice and stored at 
-80°C until use. Total RNA was isolated from the above brain areas using TRIzol Reagent 
(Invitrogen, Germany). The RNA quality and concentration of all samples were assessed by 
NanoDropTM 1000 spectrophotometer (Peqlab, Erlangen, Germany). Due to different RNA 
concentrations in the hippocampus and ventral tegmental area, either 1.0 or 0.2 µg, respectively, 
of isolated RNA was treated with DNAse I (Roche Life Science, Indianapolis, USA) and reverse 
transcribed using random hexamer primers and Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV; Invitrogen).  
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 Real Time PCR 
mRNA expression analysis was performed using Real Time PCR with SYBR Green I detection 
kit (Qiagen, Hilden, Germany) with the following primers: 5-HT2A receptor (NM_017254.1): 
HT2A5 – 5’-AACGGTCCATCCACAGAG-3’; HT2A3 – 5’-AACAGGAAGAACACGATGC-
3’ (109-bp amplicon size; Shi et al., 2008); 5-HT2C receptor (NM_012765): HT2C5 – 5’-
ATCATGGCAGTAAGCATGG-3’; HT2C3 –  5’-ATCTTCATGATGGCCTTAGTCCG-3’ 
(302-bp amplicon size; Dracheva et al., 2009); β-actin (NM_031144): β-Act fw – 5’-
TACAATGAGCTGCGTGTG-3’; β-Act rev – 5’-CACAGCCTGGATGGCTAC-3’; 147-bp 
amplicon size). All the reactions were run in triplicates using iCycler iQ5 (BIO-RAD, USA). A 
negative control lacking cDNA was included for each primer pair. The 2-ΔΔCT
 
method was 
applied to analyze the relative changes in 5-HT2A and 5-HT2C receptor gene expression (Livak 
and Schmittgen, 2001), normalized to the mRNA level of housekeeping gene, β-actin. Results 
are shown as  means of the tested gene.  
 
Deep sequencing 
Quantification of 5-HT2C receptor mRNA variants was done using deep sequencing. The edited 
region of 5-HT2C receptor was amplified by PCR using Taq DNA Polymerase (Invitrogen) with 
the following primers: forward primer HT5C51 – 5’-XXXXXXTTTTCAACTGCGTCCATCAT 
GCACCT-3’, reverse primer HT2C3 –  5’-ATCTTCATGATGGCCTTAGTCCG-3’. For each of 
16 conditions (2 treatments: vehicle/nicotine, 4 animals per each treatment group, 2 brain areas: 
the hippocampus/ventral tegmental area) a different six nucleotide barcode (XXXXXX, e.g., 
ACTGAC, CTGACA, TGACAC) at 5’ end of the forward primer was used to differentiate 
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 between conditions. PCR products (122 bp in length) were purified by centrifugation using 
Wizard SV gel and PCR Clean Up System (Promega, Madison, USA). The quality and 
concentration of PCR amplicons were assessed by NanoDropTM spectrophotometer. 200 ng of 
each barcoded PCR product were pooled and a standard Illumina TruSeq DNA sequencing 
library was created for the barcoded pool of the 16 PCR amplicons of the targeted 5-HT2C 
receptor editing region. The library was sequenced for 2x101 nt paired-end on an Illumina HiSeq 
2000. Due to the short amplicon length, overlaps between forward and reverse read of a fragment 
were resolved using ea-utils (Aronesty, 2011) by merging forward and reverse read for each of 
the ~180 million fragments into combined reads of average length 122nt. Merged, demultiplexed 
reads were mapped onto a 5-HT2C receptor transcript reference (5’-TTTTCAACTGCGTCCATC 
ATGCACC T C T G CG CCATATCGCTGGACCGGTATGTAGCAATACGTAATCCTATTG 
AGCATAGCCGGTTCAATTCGCGGACTAAGGCCATCATGAAGAT-3’) using Burrows-
Wheeler Alignment (BWA) without seeding, allowing for up to 4 mismatches. Mappings were 
converted into the Sequence Alignment/Map (SAM) format using SAMtools (Li and Durbin, 
2009; Li et al., 2009). A custom perl script was used to obtain amplicon counts and to assess 
position specific editing for each of the amplicons. 
The following editing parameters were calculated: the level of site-specific editing of the 5-HT2C 
receptor mRNA (%), the frequency of observed 5-HT2C receptor mRNA variants (%) and the 
frequency of predicted 5-HT2C receptor protein isoform (%).  
 
Statistical Analysis 
Data are expressed as means (± SEM). Comparisons between means representing changes from 
control values were made using Student’s t-test. All comparisons were made with an experiment 
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 wise type I error rate (α) set at p < 0.05. 
 
Results 
Nicotine withdrawal increases immobility time and reduces swimming behavior in rats 
withdrawn from nicotine 
On day 3 of withdrawal from repeated (for 5 days) nicotine treatment a statistically significant 
increase in immobility time (p < 0.001) and decrease in swimming behavior (p < 0.05) was 
observed (Fig. 3). 
 
Nicotine withdrawal alters 5-HT2A and 5-HT2C receptor binding in various brain structures 
We first analyzed the effect of nicotine withdrawal on radioligand binding to 5-HT2A and 5-HT2C 
receptors in brains of rats repeatedly (for 5 days) treated with vehicle or nicotine.  
[3H]ketanserin binding to 5-HT2A receptors in animals withdrawn from repeated nicotine 
administration 
In control animals receiving vehicle repeatedly, [3H]ketanserin binding to 5-HT2A receptors in 
different areas of the rat brain varied from 3.7 to 57 fmol/mg tissue, with the maximum 
radioligand binding seen in the prefrontal cortex (Tab. 1).  
On day 3 of nicotine withdrawal, an increase in [3H]ketanserin binding to 5-HT2A 
receptors was seen in the ventral tegmental area (81%) and ventral dentate gyrus (49%), and a 
decrease in the labelling of 5-HT2A receptors appeared in the nucleus accumbens shell (39%) 
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 (Tab. 1). 
[3H]mesulergine binding to 5-HT2C receptors in animals withdrawn from repeated nicotine 
administration 
In animals receiving vehicle, [3H]mesulergine binding to 5-HT2C receptors in different areas of 
the rat brain varied from 7.5 to 234 fmol/mg tissue, with the maximum radioligand binding seen 
in the choroid plexus (Tab. 2).  
On day 3 of nicotine withdrawal, a lower (33%) level of 5-HT2C receptor labelling was 
observed in the ventral dentate gyrus, but higher (by 17%) levels of binding were seen in the 
choroid plexus (Tab. 2). 
 
Nicotine withdrawal changes the expression levels of 5-HT2A receptors, but not 5-HT2C 
receptors 
We next evaluated whether the nicotine withdrawal changes the expression levels of 5-HT2A and 
5-HT2C receptors in the hippocampus and ventral tegmental area.   
The expression level of 5-HT2A receptor gene measured by real time PCR on day 3 of 
withdrawal from repeated nicotine administration significantly decreased in the whole 
hippocampus (62%) and ventral tegmental area (57%) (Fig. 4A, B). 
No change in the level of mRNA encoding for 5-HT2C receptors was observed in the 
whole hippocampus or ventral tegmental area in rats withdrawn from chronic nicotine 
administration (Fig. 5A, B).  
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 Nicotine withdrawal affects 5-HT2C receptor mRNA editing 
We assessed whether the editing of 5-HT2C receptor mRNA in the hippocampus and ventral 
tegmental area is altered by nicotine withdrawal.   
Deep sequencing analysis of 5-HT2C receptor mRNA editing in rats treated repeatedly 
with vehicle revealed that in the whole hippocampus and ventral tegmental area the highest 
frequency (12-21%) was detected for ABD, AB, ABE and ABCD receptor mRNA variants 
(Tabs. 3, 4). Out of the 24 predicted protein isoforms, the most abundant in either of the above 
brain structures were VNV, VNI, VDI and VSV 5-HT2C receptor isoforms (Tabs. 3, 4). Editing 
was significantly lower at the A (8%; p = 0.028) and B (9%; p = 0.036) site in the hippocampus 
compared with the ventral tegmental area (Fig. 6A, B).  
 
Repeated treatment with nicotine followed by a three-day withdrawal period produced a 
statistically significant decrease (30%; p = 0.043) in the editing level at the E site in the 
hippocampus; a trend toward reduction (5%; p = 0.063) was also noted at the C editing site (Fig. 
6A). At the same time, the frequency of EC, CD and ECD 5-HT2C receptor mRNA variants 
(corresponding to IGI, ISV and IGV protein isoform, respectively) was decreased (by 19, 32 and 
42%, respectively) in nicotine withdrawn animals as compared to control group, but this did not 
reach statistical significance (p = 0.14, 0.38 and 0.25, respectively) (Tab. 3). 
In the ventral tegmental area of nicotine withdrawn animals, the frequency of CD mRNA 
variant, which corresponds to ISV receptor protein isoform, significantly decreased (28%; p = 
0.0082) (Tab. 4). The site-specific editing of 5-HT2C receptor mRNA in the ventral tegmental 
area was not altered by the drug treatment (Fig. 6B).   
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 Discussion 
Previously we have shown that administration of nicotine for 5 days produces a depression-like 
phenotype reflected by increased immobility time in the forced swim test (from day 1 to 10) 
following drug withdrawal (Zaniewska et al., 2010). Although the depression-like state seems to 
be transient and disappears on day 30 of drug withdrawal, a reduction in time spent on 
swimming, a 5-HT-related parameter (Slattery et al., 2005), was reported on withdrawal day 3 
(the present study) and persisted until day 30 (Zaniewska et al., unpublished observations). Our 
detailed pharmacological analyses performed on day 3 of nicotine withdrawal – when we 
reported the maximal depression-like behavior – revealed that pharmacological blockade of 5-
HT2A receptors and stimulation of 5-HT2C receptors significantly attenuated the depression-like 
state (Zaniewska et al., 2010). Here, for the first time, we report a dramatic increase in 
radioligand 5-HT2A receptor labelling in the ventral tegmental area and ventral dentate gyrus of 
the hippocampus and a less prominent reduction in radioligand binding in the nucleus accumbens 
shell in rats on day 3 of nicotine withdrawal. In opposition to 5-HT2A receptor binding, we 
demonstrate a decrease in 5-HT2C receptor binding in the ventral part of the dentate gyrus. In 
addition, we provide the mechanistic characteristics of the above 5-HT2A/2C receptor regulation. 
The increases in 5-HT2A receptor labelling in the ventral tegmental area and hippocampus 
during nicotine withdrawal could be potentially explained by a regional decrease in 5-HT levels. 
Indeed, our present behavioral findings showing reduced swimming – a behavior sensitive to 
changes in 5-HT neurotransmission (Slattery et al., 2005) – in rats during nicotine cessation 
partially support the above hypothesis. Moreover, a reduction in the content of 5-HT and/or its 
metabolite 5-HIAA has been found in rat hippocampus or mouse whole brain following short 
term (for 4 or 7 days) once daily nicotine (0.4 or 0.5 mg/kg) administration and its 24-h 
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 withdrawal (Benwell and Balfour, 1979; Yasuda et al., 2002). Other studies showed a decrease in 
the diencephalic 5-HT content and increased immobility time in the forced swim test in mice 
following withdrawal (days 15-60; earlier withdrawal days have not been tested) from nicotine 
(2 mg/kg; injected four times daily for 15 days), which were normalized after administration of 
the selective 5-HT reuptake inhibitor paroxetine (Mannucci et al., 2006), suggesting that reduced 
5-HT activity contributes to alterations in the forced swim test of nicotine withdrawn animals. 
Also, the enhanced electrophysiological responsiveness of dorsal raphe 5-HT neurons to 5-HT1A 
receptor agonist was reported on days 3 and 4 of withdrawal from nicotine (a 12-day exposure to 
6 mg/kg/day) delivered through osmotic mini-pumps in rats (Rasmussen and Czachura, 1997), 
suggesting decreased presynaptic 5-HT-feedback inhibition during drug cessation. Although the 
above findings were obtained using different dosing schedules/models and were assessed on 
different withdrawal days, the recurring observation is the existence of the deficit in 5-HT 
function during nicotine withdrawal. In addition, the functional supersensitivity of 5-HT2A 
receptors (evidenced by the enhanced behavioral response to 5-HT2A receptor agonist) was 
reported in rodents following 24-h or 5-day cessation of chronic (for 5 or 7 days) nicotine 
administration (Suemaru et al., 2001; Yasuda et al, 2002; Zaniewska et al., 2009).  
 
On the basis of our 5-HT2A receptor autoradiography studies using receptor antagonist 
[3H]ketanserin, which binds to high- and low-affinity state receptors with similar affinity (Lohse 
et al., 1984), we may assume that we provide information on the total density of 5-HT2A 
receptors and therefore, speculate that the augmentation in 5-HT2A receptor binding may reflect 
an increase in receptor density.  
As a first step in defining the molecular mechanism underlying the effect of nicotine 
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 withdrawal on 5-HT2A receptor binding we analyzed the transcript level of the 5-HT2A receptor 
and noted a significant decrease in 5-HT2A receptor mRNA level in both studied brain structures. 
So far, published data on the 5-HT2A receptor expression level during nicotine withdrawal 
showed no change either in the receptor density or the transcript level of 5-HT2A receptors in the 
mouse midbrain, the region containing the ventral tegmental area (Hayslett and Tizabi, 2005). 
Species differences (mice vs. rats), experimental design (twice vs. once daily nicotine injections) 
or the fact that the latter research group examined the transcript level in the early (16-18h) phase 
of drug withdrawal (vs. 72h withdrawal in our study) may account for such discrepancies.  
 
Dissociation between 5-HT2A receptor synthesis (mRNA expression) and protein 
abundance (binding assay/autoradiography) – as a part of a presumed compensatory response – 
was noted earlier by some authors after chronic administration of several drugs, including 5-
HT2A receptor agonists (5-HT or DOI) or nicotine (Ferry et al., 1994; Hayslett and Tizabi, 2005; 
Shi et al., 2008). Indeed, in vitro studies (Ferry et al., 1994) have shown that brief, but not long-
term, exposure to 5-HT evoked a transient increase in the level and stability of receptor mRNA 
and a concurrent decrease in receptor density.  
 
Taken together, one of the possible mechanisms associated with 5-HT2A receptor 
regulation following nicotine withdrawal could be regionally-specific (the hippocampus and, 
possibly, ventral tegmental area) reductions in 5-HT levels which further lead to 5-HT2A receptor 
up-regulation, thereby enhancing sensitivity of neurons to the attenuated 5-HT tone. Moreover, it 
can be speculated that the reduction in the 5-HT2A receptor synthesis in the ventral tegmental 
area and hippocampus may have occurred as a counter-regulatory mechanism to increased 
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 abundance of receptor protein in these brain areas. Certainly, identification of other regulatory 
mechanisms (e.g., post-transcriptional or post-translational receptor modifications), by which 
nicotine withdrawal leads to increased labelling of 5-HT2A receptors is a challenge for future 
research.  
Besides increased ketanserin binding to 5-HT2A receptors in the ventral tegmental area 
and ventral hippocampus, we also reported almost a 40% decrease in radioligand binding in the 
nucleus accumbens shell, a brain region implicated in the depressive phenotypes observed during 
drug withdrawal (Shirayama and Chaki, 2006). Whether the decline in 5-HT2A receptor binding 
sites in the nucleus accumbens, where 5-HT2A receptors are located on dopaminergic terminals, 
is due to the utilization of the whole pool of 5-HT2A receptor mRNA for the synthesis of the 
receptor in the ventral tegmental area, in which 5-HT2A receptors are present on the cell bodies of 
dopaminergic neurons, or due to the trafficking/internalization processes and subsequent 
degradation of 5-HT2A receptors would remain to be established in further experiments.  
 
In the present work, we also report dramatic decreases in [3H]mesulergine binding to 5-
HT2C receptors in the ventral dentate gyrus of the hippocampus during nicotine withdrawal. 
Earlier studies in rats showed reductions in 5-HT2C receptor binding in the ventral hippocampus 
(CA1), which were suggested to be linked with anhedonia (Leventopoulos et al., 2009). 
Importantly, mesulergine is an inverse agonist at 5-HT2C receptors and therefore is predicted to 
preferentially interact with the inactive (low-affinity state) form of the receptor rather than the 
active form (Barker et al., 1994; Berg et al., 1999), suggesting that when used as a radioligand it 
‘labels’ only the population of inactive receptors. Thus, the decreases in, presumably, low-
affinity 5-HT2C receptor binding sites may be either due to the general decrease in the number of 
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 receptors (receptor down-regulation) or conformational changes (availability of binding sites) in 
the receptor. While receptor down-regulation seems less probable for two reasons: 1) decreased 
5-HT level in the hippocampus (Benwell and Balfour, 1979) and/or 2) enhanced functional 
sensitivity of 5-HT2C receptors (Zaniewska et al., 2010) during nicotine withdrawal, one possible 
explanation could be the conversion of 5-HT2C receptors from low to high-affinity state (due to 
transcriptional, post-transcriptional and/or translational modifications) as a compensatory 
adaptation for the decreased availability of 5-HT.  
 
To identify mechanisms responsible for the alteration in radioligand binding in the 
hippocampus we first performed real time PCR analysis, but no significant changes in the 
transcript level of 5-HT2C receptors were seen, suggesting the existence of another mechanism 
explaining the changes in receptor binding. Using a deep sequencing method, we discovered 
decrease in the editing at the E site and a tendency for a reduction at the C site in the 
hippocampus. We also found pronounced, but non-significant, reduction in the expression of the 
ECD 5-HT2C receptor mRNA variant. It might be speculated that the expression of the predicted 
IGV receptor isoform (encoded by ECD) was also reduced, however, caution must be taken 
when estimating the receptor isoform expression directly from mRNA levels (e.g., 5-HT2A 
receptors, see above).  
 
To our knowledge, this study provides the first evaluation of 5-HT2C receptor RNA 
editing patterns in rats with a putative depression-like phenotype following nicotine withdrawal. 
In agreement with our findings, clinical data show the reduction in editing efficiency across all 
editing sites and frequency of all transcripts edited at E and C in the prefrontal cortex of 
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 depressed patients; this effect paralleled increases in highly functioning INI and AD receptor 
isoforms (Lyddon et al., 2013). Other clinical studies showed only a slight non-significant 
decrease in the frequency of E, C and D site editing (Zhu et al., 2012), no change in editing 
(Niswender et al., 2001) or even an increase in editing efficiency of site D (Iwamoto and Kato, 
2003) in the prefrontal cortex of patients with major depression. Preclinical observations show 
that the learned helplessness rat model of depression was associated with increased editing of site 
E in the cortex (Iwamoto et al., 2005). Although not completely consistent, the recurring finding 
in these studies is altered editing at E and/or C site in depression-related behaviors. It would 
certainly be of interest to perform such studies in nicotine-withdrawn individuals demonstrating 
affective-like symptoms.   
 
Importantly, editing at the E and C sites has been shown to be crucial for attenuating the 
receptor efficiency to stimulate G protein. The IGV 5-HT2C receptor variant, similarly to other 
isoforms containing glycine (VGI and VGV) at position 158 (i.e., edited at both E and C site) in 
humans, has been demonstrated to exhibit the most prominent reduction in agonist potency for 
G-protein coupling stimulation compared with the non-edited INI 5-HT2C receptor isoform 
(Wang et al., 2000). In addition, the fully edited VGV receptor isoform has been shown to have 
the lowest ligand independent (constitutive) receptor activity, while the partially edited VSV or 
non-edited INI receptor isoforms exhibited the intermediate or the highest levels of constitutive 
activity, respectively (Marion et al., 2004; Nisewender et al., 2001). At the behavioral level, mice 
solely expressing the VGV isoform of the 5-HT2C receptor exhibited an antidepressant-like 
phenotype (evidenced as decreased immobility time in the forced swim test), while the absence 
of editing in INI mice induced a depression-like profile (Mombereau et al., 2010). Therefore, it 
21
 can be speculated that the decrease in editing in the hippocampus in the present study could 
contribute to the depression-like phenotype on day 3 of nicotine withdrawal.  
A logical reason for reduced editing during nicotine withdrawal may be the perturbations 
in tonic levels of 5-HT in the hippocampus, as they decreased editing at E and C sites and 
enhanced the expression of receptor isoforms exhibiting higher sensitivity to 5-HT (i.e., those 
edited at sites A, B and D) in the mouse forebrain neocortex (Gurevich et al., 2002a). Reduced 5-
HT tone, through reduced 5-HT2C receptor mRNA editing, may decrease the synthesis of low-
affinity state receptors, and therefore lead to the attenuated binding of [3H]mesulergine – a ligand 
preferring low-affinity state receptors. This argument is further supported by the finding that 
mice solely expressing VGV 5-HT2C receptor isoform – occurring predominantly in the low 
affinity receptor state – exhibited enhanced [3H]mesulergine binding (Martin et al., 2013).  
Therefore, in opposite direction, we could expect that decrease in editing at E and C sites (i.e., 
decrease in the expression of Gly-containing receptor isoforms) during nicotine withdrawal leads 
to the reduction in radioligand binding to these – more active – receptors. At the behavioral level, 
this could be reflected by enhanced functional response of these receptors to their agonist 
(Zaniewska et al., 2010). 
 
There is some concern, however, regarding the physiological role of changes in editing at 
sites E and C corresponding to receptor transcripts representing < 2% of all receptor variants. 
Since these rare isoforms may be expressed on specific types of neurons or can be linked with 
specific environmental stimuli, their importance cannot be discounted. Further studies are 
necessary to target these discrete populations of receptors. 
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 It must be mentioned that there is inconsistency in the brain regions used for 
autoradiographic and transcript analyses (ventral dentate gyrus vs. whole hippocampus). 
Certainly, the use of the same subfields of the hippocampus would provide more consistency 
between two analyses. However, since the expression of 5-HT2C receptors in the dorsal 
hippocampus is sparse (cf. Holmes et al., 1995), it seems doubtful that subtle changes noted in 
editing of 5-HT2C receptor RNA are due to the fact that for this analysis we used the whole 
hippocampus instead of the ventral dentate gyrus. 
In the present work we also assessed the 5-HT2C receptor editing in the ventral tegmental 
area, a brain area in which we did not observe significant changes in [3H]mesulergine binding to 
5-HT2C receptors or transcript level of the receptor during nicotine withdrawal. Here, we noted 
significantly lower (28%) levels of the mRNA variant CD encoding for the ISV protein isoform. 
As shown previously, the ISV receptor isoform did not affect G-protein coupling in vitro (Wang 
et al., 2000). Thus, decreased expression of the ISV receptor isoform in the ventral tegmental 
area during nicotine withdrawal may not have been sufficient to affect the binding of 
mesulergine to 5-HT2C receptors in this brain area.  
 
In summary, we propose that nicotine withdrawal evokes an increase in the number of 5-
HT2A receptors in ventral tegmental area and hippocampus and attenuates editing of 5-HT2C 
receptor mRNA in the hippocampus which results in a shift of the RNA editing profile towards a  
population of less edited (and thus more active) receptors.  
The present treatment approach suffers from certain limitations. In fact, nicotine was 
experimenter-delivered, in contrast to the voluntary drug intake models that better mirror the 
addictive behavior in humans. In addition, the duration of exposure of rats to nicotine was very 
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 short. Whether the changes in 5-HT2A receptor density and editing pattern of 5-HT2C receptor 
reported in the present study could be “bio-markers” of a depression-like state during nicotine 
withdrawal is a challenge for future research using more complex behavioral models (e.g., 
nicotine self-administration) and performing extend analysis on different time-points of nicotine 
withdrawal.  
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Tables 
Table 1. [3H]ketanserin binding to 5-HT2A receptors in rats withdrawn from repeated nicotine 
administration  
STRUCTURE VEH (fmol/mg tissue) 
NIC 
(fmol/mg tissue (% of VEH))
prelimbic cortex 53.43±4.56   59.54±2.05 (111) 
infralimbic cortex 56.53±4.58 54.84±2.36 (97) 
cingulate cortex 39.51±3.52   39.48±1.74 (100) 
dorsal striatum   8.68±1.55   6.77±1.13 (78) 
nucleus accumbens 
  - core 
  - shell 
 
23.34±2.68 
26.14±1.36 
 
16.50±1.72 (71) 
    15.87±2.14 (61)** 
ventral dentate gyrus 18.36±1.14     27.30±2.22 (149)* 
ventral tegmental area   3.73±0.45       6.74±0.94 (181)* 
Animals were treated with vehicle (VEH) or nicotine (NIC; 0.4 mg/kg) for five days and three 
days later they were killed by decapitation. Data are expressed as means (± SEM) of data from 4-
6 rats/group. A priori comparisons (Student’s t-test): *p < 0.05, **p < 0.01 vs. VEH group. 
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 data showed a reduction in editing at the E site and a trend toward reduction at the C site in the 
hippocampus. In the ventral tegmental area, a reduction for the frequency of CD 5-HT2C receptor 
transcript was seen. These results show that the reduction in the 5-HT2A receptor transcript level 
may be an auto-regulatory response to the increased receptor density in the hippocampus and 
ventral tegmental area during nicotine withdrawal, while decreased 5-HT2C receptor mRNA 
editing may explain the reduction of receptor labelling in the hippocampus. 
 
Introduction 
Nicotine is one of the major psychoactive constituents of tobacco smoke that has a strong abuse 
potential in humans and laboratory animals. The most common withdrawal symptoms in humans 
include nicotine craving, irritability, anxiety, difficulty of concentration, increased appetite and 
depressed mood (reviewed by Kenny and Markou, 2001; Markou, 2008). Prevention of the latter 
mood state has become an important issue in the management of nicotine-use or addiction.  
Many pharmaco-behavioral studies have shown that withdrawal from chronic nicotine 
exposure produced depression-like behavior in mice (15-day voluntary drug intake or passive 
drug administration) and rats (experimenter-delivered drug for 5 days), as measured by 
exaggerated immobility time in the forced swim test (Mannucci et al., 2006; Ribeiro-Carvalho et 
al., 2011; Zaniewska et al., 2010). The above data also showed that such behavioral sequelae 
were either completely diminished by the 5-HT precursor 5-hydroxytryptophan, or were 
attenuated by 5-HT2A receptor antagonists or 5-HT2C receptor agonists (Mannuci et al., 2006; 
Zaniewska et al., 2010). During withdrawal from repeated nicotine exposure (delivered by the 
experimenter or through osmotic mini-pumps) profound changes in the 5-HT system (i.e., 
significant reductions in brain 5-HT content and/or neurotransmitter turnover) have been found 
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 ACD       
ABCD   
      0.68±0.10 
    12.42±0.62 
      0.69±0.02 
    12.56±0.26 
VSV 13.10±0.55 13.25±0.27
AECD    
ABECD  
      0.20±0.03 
      0.37±0.01 
      0.20±0.03 
      0.39±0.02 
VGV   0.56±0.04   0.60±0.04
B        0.38±0.04       0.42±0.04 MNI  
BE    0.0059±0.0015     0.013±0.008 MDI 
BC      0.049±0.007     0.062±0.016 MSI 
BD        0.33±0.02       0.34±0.02 MNV 
BEC    0.0008±0.0002   0.0025±0.0011 MGI 
BED      0.009±0.005     0.004±0.001 MDV 
BCD      0.066±0.018     0.083±0.009 MSV 
BECD  0.00078±0.0003 0.00036±0.00018 MGV 
E        0.21±0.02       0.19±0.02 IDI 
EC      0.088±0.007     0.071±0.007 IGI 
ED        0.28±0.09       0.23±0.02 IDV 
ECD      0.067±0.022     0.039±0.003 IGV 
C        0.92±0.04       0.91±0.05 ISI 
CD        1.41±0.47       0.96±0.10 ISV 
D        3.11±0.86       2.83±0.09  INV 
Animals were treated with vehicle (VEH) or nicotine (NIC; 0.4 mg/kg) for five days and three 
days later they were killed by decapitation. RNAs from the hippocampus were isolated, reverse 
transcribed and amplified by PCR and deep sequenced. 5-HT2C receptor mRNA variants (e.g., 
AB, ABE, ABC) and the corresponding amino acid isoforms (e.g., INI, VNI) are indicated. Data 
are expressed as frequency means (± SEM) of data from 4 rats/group. 
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 Table 4. Frequency for the detected 5-HT2C receptor mRNA variants and predicted amino acid 
isoforms in the ventral tegmental area of rats withdrawn from repeated nicotine administration 
mRNA  
variant 
% amino acid 
isoform 
% 
VEH NIC VEH NIC 
None       4.20±0.23        9.26±5.07 INI  
A    
AB  
      6.01±0.14 
    13.95±0.63 
       5.78±0.19 
     14.44±1.16 
VNI 19.95±0.76 20.23±1.29
AE  
ABE  
      0.12±0.02 
    15.43±0.36 
       0.15±0.01 
     13.09±1.45 
VDI 15.55±0.35 13.25±1.46
AC  
ABC        
      1.17±0.05 
      9.78±0.08 
       1.12±0.08 
       9.81±0.75 
VSI 10.94±0.11 10.93±0.71
AD  
ABD   
      1.92±0.11 
    21.44±0.05 
       1.92±0.10 
     20.56±0.65 
VNV 23.36±0.16 22.48±0.74
AEC     
ABEC  
      0.27±0.03 
      0.50±0.06 
       0.30±0.08 
       0.50±0.05 
VGI   0.76±0.04   0.80±0.05
AED       
ABED    
    0.084±0.003 
      1.27±0.09 
     0.087±0.049 
       1.00±0.22 
VDV   1.35±0.10   1.08±0.19
ACD       
ABCD   
      0.55±0.05 
    14.76±0.70 
       0.61±0.03 
     13.05±0.62 
VSV 15.31±0.67 13.66±0.63
AECD    
ABECD  
      0.12±0.03 
      0.43±0.04 
       0.09±0.01 
       0.51±0.06 
VGV   0.55±0.07   0.59±0.07
B        0.37±0.05        0.36±0.06 MNI  
BE      0.017±0.015      0.011±0.005 MDI 
BC        0.12±0.02        0.12±0.03 MSI 
BD        0.51±0.04        0.47±0.04 MNV 
BEC  0.00047±0.00037 0.00055±0.00033 MGI 
BED    0.0092±0.0066      0.010±0.009 MDV 
BCD        0.19±0.03        0.13±0.03 MSV 
BECD    0.0004±0.0002 0.00046±0.00018 MGV 
E        0.18±0.04        0.22±0.04 IDI 
EC      0.077±0.024      0.090±0.023 IGI 
ED        0.18±0.03        0.16±0.01 IDV 
ECD      0.022±0.005      0.027±0.010 IGV 
C        1.10±0.14        1.09±0.06 ISI 
CD        0.83±0.06        0.60±0.01** ISV 
D        1.86±0.12        1.90±0.16 INV 
Animals were treated with vehicle (VEH) or nicotine (NIC; 0.4 mg/kg) for five days and three 
days later they were killed by decapitation. RNAs from the ventral tegmental area were isolated, 
reverse transcribed and amplified by PCR and deep sequenced. 5-HT2C receptor mRNA variants 
(e.g., AB, ABE, ABC) and the corresponding amino acid isoforms (e.g., INI, VNI) are indicated. 
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 Data are expressed as frequency means (± SEM) of data from 4 rats/group. Student’s t-test: **p 
< 0.01 vs. VEH group. 
 
 
Figure legends 
Fig. 1. Editing of 5-HT2C receptor mRNA. 5-HT2C receptor RNA undergoes adenosine-to-
inosine (recognized as guanosines by ribosomes) RNA editing (named A, B, E, C and D) 
resulting in the generation of different mRNA variants. This further yields multiple amino acid 
sequences within the second intracellular loop of the receptor, i.e., editing at A or A/B sites 
generates valine (Val; V) at this site, editing at B site converts isoleucine (Ile; I) into methionine 
(Met; M). Editing at the E site generates aspartate (Asp; D), editing at C site generates serine 
(Ser; S), while editing at both E and C generates glycine (Gly; G). Editing at D site converts I 
into V. INI – the non-edited receptor isoform, VGV – fully edited receptor variant (Burns et al., 
1997).       
Fig. 2. Representative autoradiograms of 5-HT2A and 5-HT2C receptors in the brain of rats 
receiving repeated vehicle treatment. The grey outlines in the left panel (A) show the brain areas 
in which optical densities were quantified. Central and right panels show representative 
autoradiograms of brain [3H]ketanserin-labeled 5-HT2A receptors (B) or [3H]mesulergine-labeled 
5-HT2C receptors (C) of rats treated repeatedly with vehicle. A – prelimbic cortex, B – 
infralimbic cortex, C – cingulate cortex, D – dorsal striatum (caudate putamen), E – nucleus 
accumbens (core), F – nucleus accumbens (shell), G – choroid plexus, H – ventral dentate gyrus, 
I – substantia nigra (compact part), J – substantia nigra (reticular part), K – ventral tegmental 
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 area. 
Fig. 3. Depression-like state in rats withdrawn from nicotine (0.4 mg/kg)-repeated administration 
measured in the forced swim test. The following parameters were measured: immobility, 
swimming and climbing in rats on day 3 of withdrawal from a 5-day nicotine or vehicle 
treatment. The results are shown as mean time (±SEM) of data from 7 rats/group. Student’s t-
test: *p < 0.05, ***p < 0.001 vs. VEHICLE group. 
Fig. 4. The transcript level of 5-HT2A receptor in the rat brain. Animals were treated with vehicle 
or nicotine (0.4 mg/kg) for five days and three days later they were killed by decapitation. 5-
HT2A receptor transcript level was analyzed in the whole hippocampus (A) and ventral tegmental 
area (B) by real time quantitative PCR. Data were normalized to β-actin and represent means (± 
SEM) of data from 4 rats/group. Student’s t-test: **p < 0.01 vs. VEHICLE group. 
Fig. 5. The transcript level of 5-HT2C receptor in the rat brain. Animals were treated with vehicle 
or nicotine (0.4 mg/kg) for five days and three days later they were killed by decapitation. 5-
HT2C receptor transcript level was analyzed in the whole hippocampus (A) and ventral tegmental 
area (B) by real time quantitative PCR. Data were normalized to β-actin and represent means (± 
SEM) of data from 4 rats/group.  
Fig. 6. mRNA editing level at the five editing sites (A, B, E, C and D) of the 5-HT2C receptor 
gene in the rat brain. Animals were treated with vehicle or nicotine (0.4 mg/kg) for five days and 
three days later they were killed by decapitation. 5-HT2C receptor mRNA editing status was 
analyzed in the whole hippocampus (A) and ventral tegmental area (B) by deep sequencing 
technology. Data are expressed as site-specific editing of the 5-HT2C receptor mRNA (± SEM) of 
data from 4 rats/group. Student’s t-test: *p < 0.05 vs. VEHICLE group. 
37
  
 
5-HT1c RECEPTOR 
mRNAEDITli~C 
amino acid position 
mRNA editing sites 
non-edited mRNt\ 
amino acid 
partially cditcd mRNA 
amino acid 
fully cditcd mRNA 
amino acid 
156 
AB 
t\Ut\ 
Ilc (I) 
GlJA 
Val (V) 
AUG 
Met (M) 
GUA 
Val (V) 
cuc 
Val (V) 
157 158 
EC 
CGU t\t\U 
Arg (R) Asn (N) 
e<ru AAlJ 
Arg (R) Asn (N) 
CGU GAU 
Arg (R) Asp (D) 
CGU AGU 
Arg (R) Scr (S) 
CGU ccu 
Arg (R) Gly (G) 
159 160 
D 
ccu t\UU 
Pro (P) Ilc (I) INI 
COlJ GlJlJ 
Arg(R) Val (V) VNV 
CGU AUU 
Arg (R) Ile (I) MDI 
CGU GUU 
Arg(R) Val (V) vsv 
CGU cuu 
Arg (R) Val (V) VGV 
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40
  
A 
1,4 
~ 1,2 0::: 
E 
c: 1,0 
+l 
(.) 
C'CI 
I 0,8 c:l. 
1::: 
0 ..... 
Q. 0,6 
<II 
(.) 
<II ... 0,4 
<t 
"' 5: 0,2 I 
I() 
0,0 
B 
h ippocampus 
** 
REPEATED TREATMENT 
(DAYS: 1-S) : 
c:J VetCLE 
~ NICOTIINE 
ventral tegmental area 
** 
41
  
 
1,4 
~ 1,2 ~ 
E 
1: .. 1,0 
0 
CO 
I 0,8 CQ. 
1:: 
0 
... 
Q. 0,6 
Q,) 
0 
Q,) ... 0,4 
() 
N 
~ 0,2 
I 
1/) 
0,0 
A B 
hippocampus 
REPEATED TREATMENT 
(DAYS: 1-5): 
c:::::J VIHCLE 
cs:::3 IIICOTINE 
ventral tegmental area 
42
  
 
100 
:::-
.s 
B so 
?J. 
-Cl 
.E 60 
~ 
'0 
Q) 
(,) 
!E 40 
(,) 
Q) 
0.. 
1/) 
~ 20 
~ 
(/) 
0 
A 
A 
hippocampus 
B E c D 
B 
A 
REPEATEO TREATMENT 
(OAYS: 1·5): 
c:::J VEHICLE 
es:::!! NICOTlNE 
ventral tegmental area 
B E c D 
43
